Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neuraxpharm Allies With Panaxia On Cannabis Portfolio

Launching In Germany, With Other European Countries To Follow

Executive Summary

CNS specialist Neuraxpharm has struck a deal with Israel’s Panaxia to market medical cannabis products in Europe, starting in Germany.

You may also be interested in...



Neuraxpharm And Panaxia Take Cannabis Tablets To France

Neuraxpharm and Panaxia have continued to push forward with their partnership on medical cannabis, exporting sublingual tablets to France as part of a pilot program organized by local regulator ANSM.

Neuraxpharm And Panaxia Pioneer Medical Cannabis Extract For Vaporization In Europe

Neuraxpharm and Panaxia have become the first companies in the world to market medical cannabis extract, under the joint brand Naxiva-Panaxol, for vaporization in Germany. Under the agreement, the extracts will be manufactured by Panaxia and marketed in Germany by Neuraxpharm. 

Neuraxpharm and Panaxia Partner For Poland, After Germany And France

CNS specialist Neuraxpharm has announced expanding its strategic collaboration with Panaxia Labs Israel for advanced medical cannabis-based pharmaceutical products to Poland, after Germany and France. The companies expect sale of the cannabis portfolio to commence in the first half of 2022.

 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB149778

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel